Characteristics | all patients | CD56 positive | CD56 negative | p value |
---|---|---|---|---|
n = 370 | n = 250 | n = 120 | ||
n (%) | n (%) | n (%) | ||
Sex | ||||
Male | 203 (54.9) | 129 (51.6) | 74 (61.7) | 0.07 |
Female | 167 (45.1) | 121 (48.4) | 46 (38.3) | |
Median age (range) [years] | 56 (33–65) | 56 (33–65) | 57 (33–65) | 0.59 |
MM subtype | ||||
IgG | 185 (50.0) | 137 (54.8) | 48 (40.0) | 0.00 |
IgA | 73 (19.7) | 54 (21.6) | 19 (15.8) | |
IgD | 22 (5.9) | 5 (2.0) | 17 (14.2) | |
Light chain only | 78 (21.1) | 48 (19.2) | 30 (25.0) | |
Non-secretory | 12 (3.2) | 6 (2.4) | 6 (5.0) | |
ISS stage | ||||
I | 78 (21.1) | 46 (18.4) | 32 (26.7) | 0.11 |
II | 123 (33.2) | 90 (36.0) | 33 (27.5) | |
III | 169 (45.7) | 114 (45.6) | 55 (45.8) | |
Hemoglobin | ||||
< 100 g/L | 229 (61.9) | 160 (64.0) | 69 (57.5) | 0.23 |
≥ 100 g/L | 141 (38.1) | 90 (36.0) | 51 (42.5) | |
Serum creatinine | ||||
≤ 2 mg/dL | 309 (83.5) | 210 (84.0) | 99 (82.5) | 0.72 |
> 2 mg/dL | 61 (16.5) | 40 (16.0) | 21 (17.5) | |
Corrected serum calcium | ||||
≤ 2.75 mmol/L | 323 (87.3) | 214 (85.6) | 109 (90.8) | 0.16 |
> 2.75 mmol/L | 47 (12.7) | 36 (14.4) | 11 (9.2) | |
Lactate dehydrogenase | ||||
≤ 250 U/L | 318 (85.9) | 219 (87.6) | 99 (82.5) | 0.19 |
> 250 U/L | 52 (14.1) | 31 (12.4) | 21 (17.5) | |
Cytogenetic abnormalities by FISH | ||||
del(17p13) | ||||
abnormality | 40 (10.8) | 30 (12.0) | 10 (8.3) | 0.29 |
non-abnormality | 330 (89.2) | 220 (88.0) | 110 (91.7) | |
t(14; 16) | ||||
abnormality | 15 (4.1) | 2 (0.8) | 13 (10.8) | 0.00 |
non-abnormality | 355 (95.9) | 248 (99.2) | 107 (89.2) | |
t(4; 14) | ||||
abnormality | 69 (18.6) | 67 (26.8) | 2 (1.7) | 0.00 |
non-abnormality | 301 (81.4) | 183 (73.2) | 118 (98.3) | |
Induction regimes | ||||
Bortezomib based | 167 (45.1) | 114 (45.6) | 53 (44.2) | 0.90 |
IMiD based | 30 (8.1) | 21 (8.4) | 9 (7.5) | |
Bortezomib and IMiD based | 173 (46.8) | 115 (46.0) | 58 (48.3) | |
ASCT | ||||
Yes | 194 (52.4) | 137 (54.8) | 57 (47.5) | 0.19 |
No | 176 (47.6) | 113 (45.2) | 63 (52.5) |